BIOMAT Database Logo BIOMAT Database Logo

Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. 1991

M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Department of Bacteriology, Fukushima Medical College, Japan.

In the search for 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine (HEPT) derivatives, we have found several 5-ethyl-6-(phenylthio)uracil analogues to be highly potent and selective inhibitors of human immunodeficiency virus (HIV) type 1. 1-Benzyloxymethyl-5-ethyl-6-phenylthiouracil, the most potent congener of the series, inhibits HIV-1 replication in a variety of cell systems, including peripheral blood lymphocytes, at a concentration of 1.5-7.0 nM, which is lower by a factor of 10(3) than the 50% antivirally effective concentration of the parent compound HEPT. The 5-ethyl-6-(phenylthio)uracil analogues, like HEPT itself, do not inhibit HIV-2 replication but do inhibit replication of 3'-azido-3'-deoxythymidine-resistant mutants of HIV-1. 1-Benzyloxy-methyl-5-ethyl-6-phenylthiouracil and its congeners are targeted at the HIV-1 reverse transcriptase (RT). They do not inhibit HIV-2 RT. They do not need to be metabolized to exert their inhibitory effect on HIV-1 RT. Yet this inhibitory effect is competitive with the natural substrate dTTP. The HEPT derivatives represent a group of RT inhibitors with a unique mode of interaction with HIV-1 RT.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013941 Thymine One of four constituent bases of DNA. 5-Methyluracil,5 Methyluracil
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.
March 1993, Proceedings of the National Academy of Sciences of the United States of America,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives.
August 1990, FEBS letters,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
May 1995, Journal of medicinal chemistry,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives.
June 1997, Antimicrobial agents and chemotherapy,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase.
July 1991, Proceedings of the National Academy of Sciences of the United States of America,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Interaction of the reverse transcriptase of human immunodeficiency virus type 1 with DNA.
October 1994, Biochemistry,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
In vitro inhibition of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase by gold(III) porphyrins.
September 2004, Chembiochem : a European journal of chemical biology,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Human Immunodeficiency Virus type 1 reverse transcriptase.
February 1996, Biological chemistry Hoppe-Seyler,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Synthesis and anti-human immunodeficiency virus type 1 (HIV-1) activity of 3-substituted derivatives of 3'-azido-3'-deoxythymidine (AZT), and inhibition of HIV-1 reverse transcriptase by their 5'-triphosphates.
April 1992, Chemical & pharmaceutical bulletin,
M Baba, and E De Clercq, and H Tanaka, and M Ubasawa, and H Takashima, and K Sekiya, and I Nitta, and K Umezu, and H Nakashima, and S Mori
Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
June 2006, Biochemistry,
Copied contents to your clipboard!